Last checked at 18 Nov 2022 19:49
TRADING UPDATES: Joules nomad resigns; Pharma C loss narrows
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News:
Read more
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- Stock Screeners
- Share Chat
- FX
- News & RNS
- Events
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Faron Pharmaceuticals Share News (FARN)
FARN Share
Price
FARN Share
News
FARN Share
Chat
FARN Share
Trades5
FARN
Live RNS
FARN Share
Charts
FARN Level 2
Console
FARN Live
Share Price
FARN Broker
Ratings
FARN Directors
Deals
FARN Financial
Diary
FARN
Fundamentals
FARN Short
Positions
FARN
Media
Faron Pharmaceuticals Information
Share Price Information for Faron Pharmaceuticals (FARN)
Share Price is delayed by 15 minutes
Get Live Data
Share Price:
177.50
Bid:
170.00
Ask:
185.00
Change:
0.00 (0.00%)
Spread:
15.00 (8.824%)
Open:
177.50
High:
177.50
Low:
177.50
Prev. Close:
177.50
Last checked at -
Watchlists are a member only feature
Login to your account
Don't have an account? Click here to register.Dosing begins in Faron's study of 'Clevegen' drug
Fri, 14th Dec 2018 15:57
(Sharecast News) - Clinical stage biopharmaceutical company Faron Pharmaceuticals announced on Friday that the first patient has successfully been dosed in the phase I/II MATINS study of Clevegen, its wholly-owned novel precision cancer immunotherapy drug.The AIM-traded firm said the study, being initiated at Helsinki and Oulu University Hospitals in Finland, was a first-in-human open label phase I/II clinical trial to investigate the safety and efficacy of Clevegen in selected metastatic or inoperable solid tumours.It described Clevegen as a novel anti-Clever-1 antibody, which caused changes in the immune environment of solid tumours by switching Clever-1 positive immune suppressive macrophages to immune active macrophages.Clever-1, a cell surface receptor expressed mainly by tumour vasculature and monocytes/macrophages, had been shown to promote tumour growth, to control cell-mediated immunity, and to participate in the control of B cell response and antibody production, Faron claimed.In pre-clinical models, inhibition of Clever-1 decreased tumour-associated macrophages and myeloid-derived suppressor cells within the tumour, and activated tumour-killing CD8+ cells, leading to what the company called "robust" anti-tumour activity.The treatment, if successful, could ultimately be used as a standalone therapy or in combination with other immunotherapies such as PD-1/PD-L1 inhibitors.Faron said the initial dosing level in the study was 0.3mg/kg, increasing to 1mg/kg, 3 mg/kg and 10mg/kg.The intention was to reach the maximum 10mg/kg dosing level during the first half of 2019, and to study Clever-1 occupancy in circulating monocytes from bone marrow to tumour.Breaking down that migration and converting the monocytes from an immune-suppressive to immune-activating phenotype were the main goals of the first part of the study, together with tolerability and safety observations.Faron said its scientific network had also informed it that Clever-1 presence in glioblastoma patients with very few treatment options was associated with poor survival.The company therefore intended to file a separate protocol to study those cancer patients suffering from such "aggressive" brain tumours."We are delighted that Clevegen has advanced into the clinic," said Faron chief executive officer Dr Markku Jalkanen."We have already seen promising pre-clinical and ex-vivo human data, and so this is a significant step in helping us to further understand the potential of this novel therapy."We are pleased to have achieved such rapid progress with our Clevegen programme so far and look forward to the opening of further trial sites and the expansion of the study in Europe and US."
More News
31 Oct 2022 19:58
TRADING UPDATES: 4Global wins deal; James Cropper profit warning
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:
Read more14 Oct 2022 11:14
Faron Pharmaceuticals shares down as raises EUR8.4 million in placing
(Alliance News) - Faron Pharmaceuticals Ltd shares declined on Friday, after it said it has raised EUR8.4 million from a share placing.
Read more13 Oct 2022 21:17
TRADING UPDATES: Bidstack names new COO; Fintel expands deal
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:
Read more25 Aug 2022 12:10
REPEAT: Faron Pharma half-year loss widens on higher R&D spending
(Alliance News) - Faron Pharmaceuticals Ltd on Thursday said its interim loss widened, as the company reported higher research and administrative expenses and remained revenue-less.
Read more25 Aug 2022 11:43
Faron Pharmaceuticals half-year loss widens on higher R&D spending
(Alliance News) - Faron Pharmaceuticals Ltd on Thursday said its interim loss widen, as the company reported higher research and administrative expenses and remained revenue-less.
Read more18 Aug 2022 16:02
UK earnings, trading statements calendar - next 7 days
| Friday 19 August | |
| Apax Global Alpha Ltd | Half Year Results |
| Kingspan Group PLC | Half Year Results |
| Newcrest Mining Ltd | Full Year Results |
| Monday 22 August | |
| Smoove PLC | Full Year Results |
| Tuesday 23 August | |
| Aferian PLC | Half Year Results |
| John Wood Group PLC | Half Year Results |
| Wednesday 24 August | |
| Costain Group PLC | Half Year Results |
| Lookers PLC | Half Year Results |
| Standard Chartered PLC | Half Year Results |
| Thursday 25 August | |
| Amigo Holdings PLC | Q1 Results |
| Anglo Pacific Group PLC | Half Year Results |
| Benchmark Holdings PLC | Q3 Results |
| CRH PLC | Half Year Results |
| Faron Pharmaceuticals Ltd | Half Year Results |
| Grafton Group PLC | Half Year Results |
| Harbour Energy PLC | Half Year Results |
| Hays PLC | Full Year Results |
| Hunting PLC | Half Year Results |
| Macfarlane Group PLC | Half Year Results |
| Morses Club PLC | Full Year Results |
| South32 Ltd | Full Year Results |
| Copyright 2022 Alliance News Limited. All Rights Reserved. | |
30 Jun 2022 15:59
UK shareholder meetings calendar - next 7 days
| Friday 1 July | |
| All Star Minerals PLC | GM re name change to Marula Mining |
| Monday 4 July | |
| Active Energy Group PLC | AGM |
| Clean Invest Africa PLC | AGM |
| Securities Trust of Scotland PLC | AGM |
| Tuesday 5 July | |
| Immediate Acquisition PLC | AGM |
| Marks & Spencer Group PLC | AGM |
| Open Orphan PLC | AGM |
| Saga PLC | AGM |
| Smartspace Software PLC | AGM |
| Young & Co's Brewery PLC | AGM |
| Wednesday 6 July | |
| Assura PLC | AGM |
| ContourGlobal PLC | GM re acquisition by KKR |
| GSK PLC | GM re Consumer Healthcare demerger, Haleon listing |
| Mining Minerals & Metals PLC | AGM |
| PCF Group PLC | GM re director allotment authority |
| Puma Alpha VCT PLC | AGM |
| Shires Income PLC | AGM |
| Sirius Real Estate Ltd | AGM |
| Strategic Minerals PLC | AGM |
| Worldwide Healthcare Trust PLC | AGM |
| Thursday 7 July | |
| C&C Group PLC | AGM |
| Distil PLC | AGM |
| Emmerson PLC | AGM |
| Faron Pharmaceuticals Ltd | GM re issuance of shares |
| FD Technologies PLC | AGM |
| Great Portland Estates PLC | AGM |
| Greencare Capital PLC | AGM |
| J Sainsbury PLC | AGM |
| JPMorgan European Growth & Income PLC | AGM |
| Land Securities Group PLC | AGM |
| Likewise Group PLC | GM re approval of waiver by takeover/merger panel |
| N Brown Group PLC | AGM |
| Octopus Apollo VCT PLC | AGM |
| Peel Hunt Ltd | AGM |
| Pets At Home Group PLC | AGM |
| Puma VCT 13 PLC | AGM |
| Severn Trent PLC | AGM |
| TomCo Energy PLC | AGM |
| Copyright 2022 Alliance News Limited. All Rights Reserved. | |
28 Jun 2022 18:03
IN BRIEF: Faron raises EUR5 million for bexmarilimab development
Faron Pharmaceuticals Ltd - Turku, Finland-based clinical stage biopharmaceutical company - Conducts private placing to raise EUR5 million in 2.0 million newly issued treasury shares at EUR2.49 each. Once the funds are received, Faron expects to have sufficient working capital to last until the first quarter of 2023. Net proceeds will be largely used for the acceleration of the clinical development program and manufacturing of bexmarilimab, its immunotherapy asset.
Read more15 Jun 2022 19:24
IN BRIEF: Faron Pharma reveals topline results from MATINS trial
Faron Pharmaceuticals Ltd - Turku, Finland-based clinical stage biopharmaceutical company - Announces top-line overall survival results from its phase 1/2 'Macrophage Antibody To Inhibit Immune Suppression study, which investigated the safety and efficacy of bexmarilimab monotherapy in ten different hard-to-treat or on operable solid tumour cohorts.
Read more8 Jun 2022 16:54
IN BRIEF: Faron Pharma doses first patient in bexmarilimab study
Faron Pharmaceuticals Ltd - Turku, Finland-based clinical stage biopharmaceutical company - Doses first patient in the phase I/II BEXMAB study. The study is investigating bexmarilimab, Faron's wholly-owned precision immunotherapy asset, in combination with azacitidine in multiple hematological malignancies. This marks the first time bexmarilimab is being assessed as part of a clinical study in hematologic malignancies, Faron explains.
Read more16 May 2022 17:35
IN BRIEF: US and Finland approve Faron's bexmarilimab study
Faron Pharmaceuticals Ltd - Turku, Finland-based clinical stage biopharmaceutical company - US Food & Drug Administration and Finnish Medicines Agency clear company's investigational new drug application to start its BEXMAB study, which is for assessing the safety, tolerability and efficacy of precision cancer immunotherapy known as bexmarilimab.
Read more12 May 2022 19:45
TRADING UPDATES: Belluscura to raise GBP5 million; React buys
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:
Read more8 Apr 2022 19:30
IN BRIEF: Faron Pharmaceuticals CEO buys shares worth EUR71,000
Faron Pharmaceuticals Ltd - Turku, Finland-based clinical stage biopharmaceutical company - Chief Executive Markku Jalkanen buys 25,000 shares at an average price of EUR2.82, worth EUR70,533, on Tuesday.
Read more5 Apr 2022 20:45
TRADING UPDATES: Rambler ups production; SRT Marine anticipates loss
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:
Read more